| Literature DB >> 24527219 |
David Drozek1, Hans Diehl2, Masato Nakazawa3, Tom Kostohryz4, Darren Morton5, Jay H Shubrook6.
Abstract
Most Western chronic diseases are closely tied to lifestyle behaviors, and many are preventable. Despite the well-distributed knowledge of these detrimental behaviors, effective efforts in disease prevention have been lacking. Many of these chronic diseases are related to obesity and type 2 diabetes, which have doubled in incidence during the last 35 years. The Complete Health Improvement Program (CHIP) is a community-based, comprehensive lifestyle modification approach to health that has shown success in addressing this problem. This pilot study demonstrates the effectiveness of CHIP in an underserved, rural, and vulnerable Appalachian population. Two hundred fourteen participants in CHIP collectively demonstrated significant reductions in body mass index, systolic and diastolic blood pressure, and fasting blood levels of total cholesterol, low-density lipoprotein, and glucose. If these results can be repeated in other at-risk populations, CHIP has the potential to help reduce the burden of preventable and treatable chronic diseases efficiently and cost-effectively.Entities:
Year: 2014 PMID: 24527219 PMCID: PMC3914283 DOI: 10.1155/2014/798184
Source DB: PubMed Journal: Adv Prev Med
Comparison of gender and mean age distribution in participants attending the Athens, OH, CHIP classes versus those who attended CHIP classes in the US, excluding those attending the Athens classes (Rankin et al. [8]).
| Characteristics | Athens | Rankin |
|---|---|---|
| Total | 225 | 5,066 |
| Male | 63 | 1,694 |
| Female | 162 | 3,372 |
| % male | 28 | 33 |
| % female | 72 | 67 |
| Age: mean (range) | 56.0 (24–81) | 52.7 (44–71) |
Mean changes in selected risk factors in 225 participants of the Athens, OH, CHIP classes, compared to 5066 participants who participated in CHIP interventions in the US (Rankin et al. [8]).
| Variables | Athens (1) | Rankin study (2) |
| ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Δ (%) | SD |
|
| Δ (%) | SD |
| ||
| BMI (kg/m2) | 208 | −3.5 | 4.0 | <0.001 | 4536 | −3.2 | 3.0 | <0.001 | >0.2 |
| SBP (mmHg) | 203 | −4.7 | 11.5 | <0.001 | 4579 | −4.9 | 18.7 | <0.001 | >0.2 |
| DBP (mmHg) | 203 | −1.7 | 13.6 | 0.085 | 4577 | −5.3 | 12.9 | <0.001 | <0.001 |
| TC (mg/dL) | 214 | −10.3 | 13.2 | <0.001 | 4674 | −11.0 | 13.8 | <0.001 | >0.2 |
| LDL (mg/dL) | 210 | −10.3 | 21.5 | <0.001 | 4568 | −13.0 | 21.1 | <0.001 | 0.080 |
| HDL (mg/dL) | 214 | −10.2 | 13.0 | <0.001 | 4673 | −4.7 | 8.8 | <0.001 | <0.001 |
| TG (mg/dL) | 214 | 0.0 | 38.0 | >0.2 | 4669 | −7.7 | 42.8 | <0.001 | 0.005 |
| FPG (mg/dL) | 213 | −4.1 | 11.1 | <0.001 | 3689 | −6.1 | 21.3 | <0.001 | 0.018 |
(a)
| Risk factor |
|
|
| Baseline | Post-intervention | Δ | Δ |
|
Cohen's | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post-intervention | Mean SD | Mean SD | Mean | % | ||||||
| BMI (kg/m2) | |||||||||||
| 18.5–24.9 | 35 | 51 | 31 (<0.001) | 22.7 | 1.7 | 22.3 | 2.6 | −0.4 | −1.8% | >0.2 | 0.20 |
| 25–30 | 57 | 58 | 27.3 | 1.3 | 26.1 | 1.4 | −1.2 | −4.4% | <0.001 | 1.90 | |
| >30 | 116 | 99 | 37.6 | 6.4 | 36.2 | 6.2 | −1.4 | −3.7% | <0.001 | 1.51 | |
| SBP (mmHg) | |||||||||||
| <120 | 66 | 104 | 38 (<0.001) | 111.3 | 8.3 | 113.0 | 10.9 | 1.7 | 1.5% | 0.169 | −0.17 |
| 120–139 | 91 | 78 | 130.3 | 5.6 | 122.7 | 12.1 | −7.6 | −5.8% | <0.001 | 0.64 | |
| 140–160 | 38 | 19 | 148.8 | 5.6 | 130.4 | 14.4 | −18.4 | −12.4% | <0.001 | 1.29 | |
| >160 | 8 | 2 | 170.4 | 10.5 | 150.2 | 21.1 | −20.2 | −11.9% | 0.01 | 1.24 | |
| DBP (mmHg) | |||||||||||
| <80 | 130 | 154 | 12 (<0.001) | 70.8 | 6.6 | 71.9 | 8.3 | 1.1 | 1.6% | 0.066 | −0.16 |
| 80–89 | 54 | 39 | 85.0 | 3.3 | 78.9 | 8.1 | −6.1 | −7.2% | <0.001 | 0.74 | |
| >90 | 19 | 10 | 94.4 | 2.6 | 82.4 | 8.9 | −12 | −12.7% | <0.001 | 1.39 | |
| TC (mg/dL) | |||||||||||
| <160 | 51 | 108 | 59 (<0.001) | 141.5 | 15.1 | 133.1 | 27.7 | −8.4 | −5.9% | 0.009 | 0.38 |
| 160–199 | 97 | 63 | 181.2 | 11.7 | 160.8 | 22.1 | −20.4 | −11.3% | <0.001 | 1.02 | |
| 200–239 | 47 | 35 | 218.3 | 10.8 | 189.2 | 26.7 | −29.1 | −13.3% | <0.001 | 1.07 | |
| 240–280 | 16 | 7 | 253.2 | 10.0 | 233.2 | 25.1 | −20 | −7.9% | 0.015 | 0.69 | |
| >280 | 3 | 1 | 303 | 29.7 | 216.3 | 55.7 | −86.7 | −28.6% | 0.192 | 1.12 | |
(b)
| Risk factor |
|
|
| Baseline | Post-intervention | Δ | Δ | P |
Cohen's | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post-intervention | Mean SD | Mean SD | Mean | % | ||||||
| LDL (mg/dL) | |||||||||||
| <100 | 78 | 115 | 52 (<0.001) | 78.3 | 18.6 | 72.9 | 23.5 | −5.4 | −6.9% | 0.114 | 0.18 |
| 100–129 | 67 | 56 | 115.0 | 8.2 | 99.5 | 18.3 | −15.5 | −13.5% | <0.001 | 0.86 | |
| 130–159 | 46 | 33 | 143.1 | 9.8 | 125.7 | 19.8 | −17.4 | −12.2% | <0.001 | 0.94 | |
| 160–190 | 14 | 6 | 169.4 | 7.0 | 145.6 | 25.1 | −23.8 | −14.0% | 0.004 | 0.92 | |
| >190 | 5 | 0 | 210.6 | 19.2 | 141.4 | 29.1 | −69.2 | −32.9% | 0.015 | 1.83 | |
| HDL (mg/dL) | |||||||||||
| <40 | 69 | 105 | 60 (<0.001) | 34.9 | 3.7 | 33.4 | 4.6 | −1.5 | −4.3% | 0.004 | 0.36 |
| 40–60 | 101 | 89 | 48.8 | 5.6 | 42.2 | 7.0 | −6.6 | −13.5% | <0.001 | 1.16 | |
| >60 | 44 | 20 | 72.1 | 13.7 | 62.5 | 15.7 | −9.6 | −13.3% | <0.001 | 0.86 | |
| TG (mg/dL) | |||||||||||
| <100 | 80 | 84 | 1.5 (>0.2) | 71.3 | 19.0 | 81.3 | 32.8 | 10.0 | 14.0% | 0.001 | −0.38 |
| 100–199 | 102 | 103 | 143.7 | 29.7 | 133.5 | 43.5 | −10.2 | −7.1% | 0.023 | 0.23 | |
| 200–400 | 29 | 26 | 256.3 | 43.0 | 206.5 | 84.5 | −49.8 | −19.4% | 0.002 | 0.63 | |
| >400 | 3 | 1 | 444.7 | 57.6 | 219.0 | 48.9 | −225.7 | −50.8% | 0.019 | 4.16 | |
| FPG (mg/dL) | |||||||||||
| <110 | 162 | 181 | 15 (<0.001) | 94.7 | 8.8 | 93.2 | 9.1 | −1.5 | −1.6% | 0.021 | 0.18 |
| 110–125 | 27 | 18 | 116.2 | 4.0 | 108.1 | 11.9 | −8.1 | −7.0% | <0.001 | 0.70 | |
| >125 | 24 | 14 | 169.1 | 52.3 | 131.6 | 29.9 | −37.5 | −22.2% | <0.001 | 0.99 | |